Enzon Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:ENZN)

$0.31 0.01 (3.33 %)
(As of 12/12/2017 05:27 AM ET)
Previous Close$0.30
Today's Range$0.29 - $0.31
52-Week Range$0.03 - $0.47
Volume70,993 shs
Average Volume40,423 shs
Market Capitalization$13.09 million
P/E RatioN/A
Dividend Yield50.68%
Beta1.28

About Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:ENZN
CUSIP29390410
Phone732-980-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio21.35%
Quick Ratio21.35%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.38 million
Price / Sales1.64
Cash FlowN/A
Price / CashN/A
Book Value$0.23 per share
Price / Book1.35

Profitability

Trailing EPSN/A
Net Income$-1,120,000.00
Net Margins4.00%
Return on Equity3.27%
Return on Assets3.12%

Miscellaneous

Employees5
Outstanding Shares44,220,000

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How often does Enzon Pharmaceuticals pay dividends? What is the dividend yield for Enzon Pharmaceuticals?

Enzon Pharmaceuticals declared a dividend on Tuesday, August 15th. Investors of record on Wednesday, August 30th will be given a dividend of $0.15 per share on Thursday, September 28th. The ex-dividend date of this dividend is Friday, September 29th. View Enzon Pharmaceuticals' Dividend History.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) posted its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a return on equity of 3.27% and a net margin of 4.00%. View Enzon Pharmaceuticals' Earnings History.

When will Enzon Pharmaceuticals make its next earnings announcement?

Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March, 23rd 2018. View Earnings Estimates for Enzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:

  • Jonathan N. Christodoro, Chairman of the Board (Age 41)
  • Andrew D. Rackear J.D., Chief Executive Officer, Secretary (Age 60)
  • Richard L. Feinstein, Chief Financial Officer, Vice President - Finance (Age 71)
  • Odysseas D. Kostas M.D., Director (Age 40)
  • Jennifer I. McNealey, Director (Age 42)

How do I buy Enzon Pharmaceuticals stock?

Shares of Enzon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of Enzon Pharmaceuticals stock can currently be purchased for approximately $0.31.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $13.09 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]


MarketBeat Community Rating for Enzon Pharmaceuticals (ENZN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enzon Pharmaceuticals (OTCMKTS:ENZN) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Enzon Pharmaceuticals (OTCMKTS:ENZN) Earnings History and Estimates Chart

Earnings by Quarter for Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS ENZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/23/2018        
8/10/2016Q3 2016$0.02$2.27 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.11)$10.01 million$10.65 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Enzon Pharmaceuticals (OTCMKTS:ENZN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Enzon Pharmaceuticals (OTCMKTS:ENZN) Dividend Information

Most Recent Dividend:9/28/2017
Annual Dividend:$0.15
Dividend Yield:48.40%
Payout Ratio:
Dividend Payments by Quarter for Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS:ENZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/15/2017$0.159/29/20178/30/20179/28/2017
12/7/2015special$0.2512/30/201512/14/201512/29/2015
7/7/2015special$0.508/13/20157/21/20158/12/2015
12/9/2014special$0.101/8/20151/12/20151/28/2015
12/9/2013special$0.4512/24/201312/16/201312/23/2013
4/23/2013special$1.605/3/20135/7/20136/4/2013
(Data available from 1/1/2013 forward)

Insider Trades

Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 0.09%
Insider Trades by Quarter for Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2016Carl C IcahnMajor ShareholderBuy694,023$0.41$284,549.43View SEC Filing  
9/19/2013Robert LebuhnDirectorSell55,926$1.72$96,192.72View SEC Filing  
8/10/2012Robert LebuhnDirectorSell1,933$6.58$12,719.14View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Enzon Pharmaceuticals (OTCMKTS ENZN) News Headlines

Source:
DateHeadline
Share Buyback Program Announced by Enzon Pharmaceuticals (ENZN) Share Buyback Program Announced by Enzon Pharmaceuticals (ENZN)
www.americanbankingnews.com - November 15 at 12:55 PM
Enzon Pharmaceuticals (ENZN) to Buyback $50.00 million in  Outstanding SharesEnzon Pharmaceuticals (ENZN) to Buyback $50.00 million in Outstanding Shares
www.americanbankingnews.com - November 15 at 12:55 PM

SEC Filings

Enzon Pharmaceuticals (OTCMKTS:ENZN) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Enzon Pharmaceuticals (OTCMKTS:ENZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enzon Pharmaceuticals (OTCMKTS ENZN) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.